



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert M. Townsend et al. Examiner: Phillip Gambel, Ph.D.
Serial No.: 09/877,987 Group Art Unit: 1645
Filed: June 8, 2001 Docket: D0009NP; 30436.53USU1
Title: METHODS FOR REGULATING A CELL-MEDIATED IMMUNE RESPONSE BY
BLOCKING LYMPHOCYTIC SIGNALS AND BY BLOCKING LFA-1-MEDIATED
ADHESION

1645
P#18
RECEIVED
JUN 19 2003
160012900

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Arlington, VA 2213-1450 on June 16, 2003.

By: 
Name: Tracy Truick

55 South Lake Avenue, Suite 710
Pasadena, California 91101
June 16, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate under 37 C.F.R. 1.8
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97(b)(3))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 190-232
- ☒ Return postcard

Please charge any and/or additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO
55 South Lake Avenue, Suite 710
Pasadena, California 91101
(626)395-7801

By: 
Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA
Customer No. 26,941



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert M. Townsend, et al. **Examiner:** Phillip Gambel, Ph.D.
Serial No.: 09/877,987 **Group Art Unit:** 1644
Filed: June 8, 2001 **Docket No.:** D0009NP/30436.53USU1
Title: METHODS FOR REGULATING A CELL-MEDIATED IMMUNE RESPONSE
BY BLOCKING LYMPHOCYTIC SIGNALS AND BY BLOCKING LFA-1
MEDIATED ADHESION

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 16, 2003.

By: 

Name: Tracy Truick

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
June 16, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. § 1.97(b)(3))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This information Disclosure Statement should be considered because it is submitted before the mailing date of the first Office Action on the merits according to 37 C.F.R. §1.97(b)(3). In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 190-232 as set forth in the Form 1449 are included herewith.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- International Publication No. WO 01/90122 A2 published November 29, 2001.
(Exhibit 190)
- International Publication No. WO 01/54732 A1 published August 2, 2001.
(Exhibit 191)
- International Publication No. WO 00/23115 published April 27, 2000. **(Exhibit 192)**
- International Publication No. WO 97/28267 published August 7, 1997. **(Exhibit 193)**
- International Publication No. WO 96/14865 published May 23, 1996. **(Exhibit 194)**
- International Publication No. WO 98/31820 published July 23, 1998. **(Exhibit 195)**
- International Publication No. WO 94/28912 published December 22, 1994.
(Exhibit 196)
- U.S. Patent No. 6,444,792 issued September 3, 2002. **(Exhibit 197)**
- International Publication No. WO 93/19767 published October 14, 1993. **(Exhibit 198)**
- International Publication No. WO 94/29436 published December 22, 1994.
(Exhibit 199)
- International Publication No. WO 95/33823 published December 14, 1995.
(Exhibit 200)
- International Publication No. WO 93/00431 published January 7, 1993. **(Exhibit 201)**
- European Patent Publication Number 0 613 944 A2 published September 7, 1994.
(Exhibit 202)
- European Patent Publication Number 0 682 039 A1 published November 15, 1995.
(Exhibit 203)
- Morton, Phillip A. et al., "Differential Effects of CTLA-4 Substitutions on the Binding of Human CD80 (B7-1) and CD86 (B7-2)," *Journal of Immunology*, 1996, 156:1047-1054 **(Exhibit 204)**
- Souza, D. et al., "Synergistic Inhibition of Established Collagen Induced Arthritis (CIA) Through Dual Inhibition of ICAM-1 and CD40L Pathways," *Arthritis and Rheumatism*, 1999, 42:S60 **(Exhibit 205)**

- U.S. Patent No. 5,968,510 issued October 10, 1999. **(Exhibit 206)**
- U.S. Patent No. 5,844,095 issued December 1, 1998. **(Exhibit 207)**
- International Publication No. WO 01/92337 published December 6, 2001
(Exhibit 208)
- Alegre, Maria-Luisa et al., "Immunomodulation of Transplant Rejection Using Monoclonal Antibodies and Soluble Receptors," *Digestive Diseases and Sciences*, 1995, 40:58-64 **(Exhibit 209)**
- Murakami, Masaaki et al., "Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells," *Proceedings of the National Academy of Sciences USA*, 1995, 93:7838-7842
(Exhibit 210)
- Peach, Robert J. et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28," *Journal of Biological Chemistry*, 1995, 270:21181-21187. **(Exhibit 211)**
- Fargeas, Christine et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4," *Journal of Experimental Medicine*, 1995, 182:667-675. **(Exhibit 212)**
- Steurer, Wolfgang et al., "Ex Vivo Coating of Islet Cell Allografts with Murin CTLA4/Fc Promotes Graft Tolerance," *Journal of Immunology*, 1995, 155:1165-1174.
(Exhibit 213)
- Guo, Yong et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA4-binding Site on Immunoglobulin C-like Domain," *Journal of Experimental Medicine*, 1995, 181:1345-1355. **(Exhibit 214)**
- Peach, Robert J. and Peter S. Linsley, "CTLA4Ig: A Novel Immunoglobulin Chimera with Immunosuppressive Properties," *Methods*, 1995, 8:116-123. **(Exhibit 215)**

- Rattis, Frédérique-Marie et al., "Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells," *European Journal of Immunology*, 1996, 26:449-453. **(Exhibit 216)**
- International Publication No. WO 98/33,513 published August 6, 1998. **(Exhibit 217)**
- U.S. Patent No. 5,851,795 issued December 22, 1998 **(Exhibit 218)**
- U.S. Patent No. 5,958,403 issued September 28, 1999. **(Exhibit 219)**
- Najafian, Nader and Mohamed H. Sayegh, "CTLA4-Ig: a novel immunosuppressive agent," *Exp. Opin. Invest. Drugs*, 2000, 9:2147-2157 **(Exhibit 220)**
- Tan, Patrick et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1," *Journal of Experimental Medicine*, 1993, 177:165-173. **(Exhibit 221)**
- Turka, Laurence A. et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection *in vivo*," *Proceedings of the National Academy of Sciences USA*, 1992, 89:11102-11105. **(Exhibit 222)**
- U.S. Patent No. 5,770,197 issued June 23, 1998. **(Exhibit 223)**
- U.S. Patent No. 6,132,992 issued October 17, 2000. **(Exhibit 224)**
- U.S. Patent No. 5,773,253 issued June 30, 1998. **(Exhibit 225)**
- U.S. Patent No. 5,885,796 issued March 23, 1999. **(Exhibit 226)**
- U.S. Patent No. 5,977,318 issued November 2, 1999. **(Exhibit 227)**
- U.S. Patent No. 5,885,579 issued March 23, 1999. **(Exhibit 228)**
- U.S. Patent No. 5,993,800 issued November 30, 1999. **(Exhibit 229)**
- U.S. Patent No. 5,916,560 issued June 29, 1999. **(Exhibit 230)**
- Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," *Cell*, 1992, 71:1085-1088. **(Exhibit 231)**
- U.S. Patent No. 5,637,481 issued June 10, 1997 **(Exhibit 232)**


Robert Townsend, et al.
Serial No. 09/877,987
Filed: June 8, 2001
Page 5

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the references are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Applicants invite the Patent Office to request additional information if necessary. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-0306.

Respectfully submitted,




Sarah B. Adriano
Registration No. 34,470
Teresa Liang
Registration No. 51,946
Practitioners for Applicants
Mandel & Adriano
55 South Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801
Customer No. 26,941

FORM 1449*

Docket Number
D0009NP;30436.53USU1Application Number
09/877,987INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATIONApplicant
Robert M. Townsend et al.Filing Date
June 8, 2001Group Art Unit
1645

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,444,792 (Exhibit 197)	September 3, 2002	Gray et al.			
	5,968,510 (Exhibit 206)	October 10, 1999	Linsley et al.			
	5,844,095 (Exhibit 207)	December 1, 1998	Linsley et al.			
	5,851,795 (Exhibit 218)	December 22, 1998	Linsley et al.			
	5,958,403 (Exhibit 219)	September 28, 1999	Strom et al.			
	5,770,197 (Exhibit 223)	June 23, 1998	Linsley et al.			
	6,132,992 (Exhibit 224)	October 17, 2000	Ledbetter et al.			
	5,773,253 (Exhibit 225)	June 30, 1998	Linsley et al.			
	5,885,796 (Exhibit 226)	March 23, 1999	Linsley et al.			
	5,977,318 (Exhibit 227)	November 2, 1999	Chou			
	5,885,579 (Exhibit 228)	March 23, 1999	Linsley et al.			
	5,993,800 (Exhibit 229)	November 30, 1999	Linsley et al.			
	5,916,560 (Exhibit 230)	June 29, 1999	Larsen et al.			
	5,637,481 (Exhibit 232)	June 10, 1997	Ledbetter et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/90122 A2 (Exhibit 190)	November 29, 2001	PCT				
	WO 01/54732 A1 (Exhibit 191)	August 2, 2001	PCT				
	WO 00/23115 (Exhibit 192)	April 27, 2000	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number

D0009NP;30436.53USU1

Application Number

09/877,987

Applicant

Robert M. Townsend et al.

Filing Date

June 8, 2001

Group Art Unit

1645

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/28267 (Exhibit 193)	August 7, 1997	PCT				
	WO 96/14865 (Exhibit 194)	May 23, 1996	PCT				
	WO 98/31820 (Exhibit 195)	July 23, 1998	PCT				
	WO 94/28912 (Exhibit 196)	December 22, 1994	PCT				
	WO 93/19767 (Exhibit 198)	October 14, 1993	PCT				
	WO 94/29436 (Exhibit 199)	December 22, 1994	PCT				
	WO 95/33823 (Exhibit 200)	December 14, 1995	PCT				
	WO 93/00431 (Exhibit 201)	January 7, 1993	PCT				
	EP 0 613 944 A2 (Exhibit 202)	September 7, 1994	EP				
	EP 0 682 039 A1 (Exhibit 203)	November 15, 1995	EP				
	WO 01/92337 (Exhibit 208)	December 6, 2001	PCT				
	WO 98/33,513 (Exhibit 217)	August 6, 1998.	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Morton, Phillip A. et al., "Differential Effects of CTLA-4 Substitutions on the Binding of Human CD80 (B7-1) and CD86 (B7-2)," <i>Journal of Immunology</i> , 1996, 156:1047-1054 (Exhibit 204)
	Souza, D. et al., "Synergistic Inhibition of Established Collagen Induced Arthritis (CIA) Through Dual Inhibition of ICAM-1 and CD40L Pathways," <i>Arthritis and Rheumatism</i> , 1999, 42:S60 (Exhibit 205)
	Alegre, Maria-Luisa et al., "Immunomodulation of Transplant Rejection Using Monoclonal Antibodies and Soluble Receptors," <i>Digestive Diseases and Sciences</i> , 1995, 40:58-64 (Exhibit 209)
	Murakami, Masaaki et al., "Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells," <i>Proceedings of the National Academy of Sciences USA</i> , 1995, 93:7838-7842 (Exhibit 210)
	Peach, Robert J. et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28," <i>Journal of Biological Chemistry</i> , 1995, 270:21181-21187. (Exhibit 211)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


 RECEIVED
JUN 19 2003
TECH CENTER 1600/2915

FORM 1449*

Docket Number

Application Number

D0009NP;30436.53USU1

09/877,987

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

Applicant

Robert M. Townsend et al.

Filing Date

June 8, 2001

Group Art Unit

1645

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Fargeas, Christine et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4," Journal of Experimental Medicine, 1995, 182:667-675. **(Exhibit 212)**

Steurer, Wolfgang et al., "Ex Vivo Coating of Islet Cell Allografts with Murin CTLA4/Fc Promotes Graft Tolerance," Journal of Immunology, 1995, 155:1165-1174. **(Exhibit 213)**

Guo, Yong et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA4-binding Site on Immunoglobulin C-like Domain," Journal of Experimental Medicine, 1995, 181:1345-1355. **(Exhibit 214)**

Peach, Robert J. and Peter S. Linsley, "CTLA4Ig: A Novel Immunoglobulin Chimera with Immunosuppressive Properties," Methods, 1995, 8:116-123. **(Exhibit 215)**

Rattis, Frédérique-Marie et al., "Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells," European Journal of Immunology, 1996, 26:449-453. **(Exhibit 216)**

Najafian, Nader and Mohamed H. Sayegh, "CTLA4-Ig: a novel immunosuppressive agent," Exp. Opin. Invest. Drugs, 2000, 9:2147-2157 **(Exhibit 220)**

Tan, Patrick et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1," Journal of Experimental Medicine, 1993, 177:165-173. **(Exhibit 221)**

Turka, Laurence A. et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo," Proceedings of the National Academy of Sciences USA, 1992, 89:11102-11105. **(Exhibit 222)**

Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," *Cell*, 1992, 71:1085-1088. **(Exhibit 231)**

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

